Abstract
Biotechnological medicines have improved the treatment of various diseases and the quality of life of patients [1]. The administration of a drug may lead to adverse events that may or may not be documented. These events affect disease progression and health expenditures [2]. Rheumatoid Arthritis (RA) is an autoimmune disease for which biotechnological medicines are prescribed. RA has serious economic impact. Especially, the annual cost of RA is 41 billion euros in the USA and 45 billion euros in Europe, which are increasing dramatically with appearance of an adverse event [3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Takeuchi T (2011) Revolutionary change in Rheumatoid arthritis management with biological therapy. Keio J Med 60:3
Pirmohamed M (2002) Adverse drug reactions – back to future. Br J Clin Pharmacol 55:486–492
Furneri G (2012) Systemic literature review on economic implications and pharmacoeconomics issues of rheumatoid arthritis. Clin Exp Rheumatol 30:73
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this paper
Cite this paper
Papadopoulos, I., Demetzos, C., Markantoni-Kyroudi, S., Souliotis, K. (2015). The Safety of Biological Medicines for Rheumatoid Arthritis. In: Vlamos, P., Alexiou, A. (eds) GeNeDis 2014. Advances in Experimental Medicine and Biology, vol 822. Springer, Cham. https://doi.org/10.1007/978-3-319-08927-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-319-08927-0_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-08926-3
Online ISBN: 978-3-319-08927-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)